OncoSec Medical Insiders
ONCSDelisted Stock | USD 0.0002 0.00 0.00% |
OncoSec Medical employs about 40 people. The company is managed by 23 executives with a total tenure of roughly 122 years, averaging almost 5.0 years of service per executive, having 1.74 employees per reported executive. Breaking down OncoSec Medical's management performance can provide insight into the firm performance.
Punit Dhillon CEO Co-Founder, CEO and President and Director |
Avtar Dhillon Chairman Independent Chairman of the Board |
OncoSec |
OncoSec Medical Management Team Effectiveness
The company has return on total asset (ROA) of (0.9284) % which means that it has lost $0.9284 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.1017) %, meaning that it created substantial loss on money invested by shareholders. OncoSec Medical's management efficiency ratios could be used to measure how well OncoSec Medical manages its routine affairs as well as how well it operates its assets and liabilities.OncoSec Medical Workforce Comparison
OncoSec Medical is considered to be number one stock in number of employees category among related companies. The total workforce of Health Care industry is now estimated at about 224. OncoSec Medical retains roughly 40.0 in number of employees claiming about 18% of equities under Health Care industry.
OncoSec Medical Notable Stakeholders
An OncoSec Medical stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as OncoSec Medical often face trade-offs trying to please all of them. OncoSec Medical's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting OncoSec Medical's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Punit Dhillon | Co-Founder, CEO and President and Director | Profile | |
Avtar Dhillon | Independent Chairman of the Board | Profile | |
David Meininger | Senior Vice President - Business Development | Profile | |
Robert Pierce | Chief Medical Officer, Vice President - Research & Development | Profile | |
Richard Slansky | CFO | Profile | |
Sara Bonstein | CFO, COO | Profile | |
Joon Kim | Director | Profile | |
James DeMesa | Independent Director | Profile | |
Annalisa Jenkins | Independent Director | Profile | |
Margaret Dalesandro | Director | Profile | |
Daniel OConnor | Director | Profile | |
Robert Ward | Independent Director | Profile | |
Anthony Maida | Independent Director | Profile | |
Gregory Mayes | Director | Profile | |
Robert CPA | VP Controller | Profile | |
Sheela MohanPeterson | Chief Legal and Compliance Officer | Profile | |
Robert Arch | CEO Pres | Profile | |
Tu MSc | VP Operations | Profile | |
Mai MD | Consultant | Profile | |
Kim Jaffe | Assistant Operations | Profile | |
CPA CFA | Exec CFO | Profile | |
Sharron Gargosky | Chief Clinical and Regulatory Officer | Profile | |
Sandra Aung | Sr Officer | Profile |
About OncoSec Medical Management Performance
The success or failure of an entity such as OncoSec Medical often depends on how effective the management is. OncoSec Medical management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of OncoSec management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the OncoSec management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company was incorporated in 2008 and is headquartered in Pennington, New Jersey. Oncosec Medical operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 54 people.
The data published in OncoSec Medical's official financial statements usually reflect OncoSec Medical's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of OncoSec Medical. For example, before you start analyzing numbers published by OncoSec accountants, it's critical to develop an understanding of what OncoSec Medical's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of OncoSec Medical's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, OncoSec Medical's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in OncoSec Medical's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of OncoSec Medical. Please utilize our Beneish M Score to check the likelihood of OncoSec Medical's management manipulating its earnings.
OncoSec Medical Workforce Analysis
Traditionally, organizations such as OncoSec Medical use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare OncoSec Medical within its industry.OncoSec Medical Manpower Efficiency
Return on OncoSec Medical Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 854.5K | |
Net Loss Per Executive | 1.5M | |
Working Capital Per Employee | 215K | |
Working Capital Per Executive | 373.9K |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the OncoSec Medical information on this page should be used as a complementary analysis to other OncoSec Medical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Consideration for investing in OncoSec Stock
If you are still planning to invest in OncoSec Medical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the OncoSec Medical's history and understand the potential risks before investing.
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum |